Patents by Inventor Clayton YATES
Clayton YATES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957674Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: January 25, 2022Date of Patent: April 16, 2024Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
-
Publication number: 20220143130Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: ApplicationFiled: November 29, 2021Publication date: May 12, 2022Inventors: Jesse M. Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Bahja Ahmed Abdi, Richard Stratton, Charles Garvin
-
Publication number: 20220062373Abstract: Aspects of the present disclosure include methods for modulating macrophage activity. Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.Type: ApplicationFiled: September 17, 2021Publication date: March 3, 2022Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates
-
Publication number: 20210401927Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: ApplicationFiled: September 15, 2021Publication date: December 30, 2021Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 11147854Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: GrantFiled: August 7, 2019Date of Patent: October 19, 2021Assignee: Riptide Bioscience, Inc.Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20210077566Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: September 22, 2020Publication date: March 18, 2021Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20200069765Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: ApplicationFiled: August 7, 2019Publication date: March 5, 2020Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 10413584Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.Type: GrantFiled: August 29, 2018Date of Patent: September 17, 2019Assignee: Riptide Bioscience, Inc.Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Publication number: 20190046601Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: October 24, 2018Publication date: February 14, 2019Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 10149886Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: GrantFiled: October 5, 2016Date of Patent: December 11, 2018Assignee: Riptide Bioscience, Inc.Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 10016480Abstract: Methods for treating a subject for pancreatic cancer via administration of small anti-inflammatory peptides are disclosed. The peptides may be administered in conjunction with another therapeutic agent, such as a chemotherapeutic agent, or therapeutic regimen. In some cases, the anti-inflammatory peptide that finds use in the subject methods has the amino acid sequence Lys-Phe-Arg-Lys-Ala-Phe-Lys-Arg-Phe-Phe (SEQ ID NO:1) or a multimer, derivative, or variant thereof.Type: GrantFiled: October 13, 2015Date of Patent: July 10, 2018Assignees: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, Riptide Bioscience, Inc.Inventors: Udo Rudloff, Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates
-
Publication number: 20170252396Abstract: Methods for treating pancreatic cancer via administration of small anti-inflammatory peptides. The peptides may be administered in conjunction with another therapeutic agent or therapeutic regimen.Type: ApplicationFiled: October 13, 2015Publication date: September 7, 2017Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Riptide Bioscience, Inc.Inventors: Udo Rudloff, Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates
-
Publication number: 20170020956Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: October 5, 2016Publication date: January 26, 2017Inventors: Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
-
Patent number: 9492499Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: GrantFiled: October 13, 2015Date of Patent: November 15, 2016Assignee: Riptide Bioscience, Inc.Inventors: Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates, Charles E. Garvin
-
Publication number: 20160101150Abstract: Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals.Type: ApplicationFiled: October 13, 2015Publication date: April 14, 2016Inventors: Jesse M. Jaynes, Henry W. Lopez, George R. Martin, Clayton Yates, Charles E. Garvin
-
Publication number: 20140302515Abstract: Kaiso, a transcriptional regulator with bimodal DNA-binding specificity, is over-expressed in breast cancer cells, and its nuclear localization is correlated with malignant and lymph node metastasis. Depleted expression of Kaiso in those cells results in a significant decrease in basal and EGF-induced cell migration, and this is associated with increased E-cadherin expression. The data reported and described herein provide significant evidence that Kaiso is involved in breast cancer invasion and metastasis. Kaiso nuclear localization is a biomarker that is associated with invasive and metastatic infiltrating ductal breast cancer that may be used to monitor, detect, and/or track the progress of disease in a patient.Type: ApplicationFiled: August 9, 2012Publication date: October 9, 2014Applicant: TUSKEGEE UNIVERSITYInventors: Clayton Yates, Timothy Turner, Jacqueline Jones-Triche
-
Publication number: 20140286868Abstract: Immortalized human cell lines derived from prostate cells are disclosed. Immortalized cells derived from a human epithelial prostate tissue cancer tumor are provided, as well as immortalized cells derived from healthy human epithelial prostate tissue from the same patient. Methods for utilizing such immortalized cell lines for researching, screening, and evaluating antimalignancy therapies and drug candidates are also disclosed.Type: ApplicationFiled: June 5, 2014Publication date: September 25, 2014Applicant: TUSKEGEE UNIVERSITYInventors: Clayton Yates, Timothy Turner
-
Publication number: 20130219531Abstract: Immortalized human cell lines derived from prostate cells are disclosed. Immortalized cells derived from a human epithelial prostate tissue cancer tumor are provided, as well as immortalized cells derived from healthy human epithelial prostate tissue from the same patient. Methods for utilizing such immortalized cell lines for researching, screening, and evaluating antimalignancy therapies and drug candidates are also disclosed.Type: ApplicationFiled: August 20, 2012Publication date: August 22, 2013Applicant: TUSKEGEE UNIVERSITYInventors: Clayton YATES, Timothy TURNER
-
Patent number: 8461118Abstract: Lytic peptides, including fusion peptides of lytic peptides conjugated with luteinizing hormone-releasing hormone or modified versions thereof to target luteinizing hormone-releasing hormone receptors, are disclosed. The lytic peptides show anti-proliferative activity against human prostate cancer cell lines, but are nontoxic to normal primary human prostate epithelial cells or to bone marrow stromal cells in co-culture. The lytic peptides have specificity for and anti-proliferative activity against prostate cancer tumor cells, and low toxicity for normal prostate cells, making the peptides useful in therapies for prostate cancer.Type: GrantFiled: July 7, 2011Date of Patent: June 11, 2013Assignee: Tuskegee UniversityInventors: Clayton Yates, Jesse Jaynes, Timothy Turner
-
Publication number: 20130012437Abstract: Lytic peptides, including fusion peptides of lytic peptides conjugated with luteinizing hormone-releasing hormone or modified versions thereof to target luteinizing hormone-releasing hormone receptors, are disclosed. The lytic peptides show anti-proliferative activity against human prostate cancer cell lines, but are nontoxic to normal primary human prostate epithelial cells or to bone marrow stromal cells in co-culture. The lytic peptides have specificity for and anti-proliferative activity against prostate cancer tumor cells, and low toxicity for normal prostate cells, making the peptides useful in therapies for prostate cancer.Type: ApplicationFiled: July 7, 2011Publication date: January 10, 2013Applicant: Tuskegee UniversityInventors: Clayton YATES, Jesse JAYNES, Timothy TURNER